Carvykti (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR) T cell therapy, has been given a more prominent position for the treatment of multiple myeloma following a Phase 3 trial showing it reduced the risk of disease progression or death by 59% compared with standard therapies. On 5 April, a new indication as a second-line therapy was approved by the US Food and Drug Administration. This followed a recommendation for an upgrade by the agency’s oncologic drugs advisory committee.
